Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960058/S177

HiResolution Bionic Ear System

Advanced Bionics · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP960058/S177

What did the FDA approve?

FDA completed review of PMA supplement P960058/S177 for the HiResolution Bionic Ear System on September 4, 2026. The supplement requested approval to remove the non-tamperproof battery door in the external processor and replace it with a validated tamperproof door in the packaged configuration of the M Zn-Air Battery Pak (CI-5501).

This is a Special (Immediate Track) supplement classified as a process change involving manufacturer, sterilizer, packager, or supplier. The decision is limited to the battery door change; it is not a new approval of the whole system. The source statement reports the requested change but does not provide independent proof of safety or clinical effectiveness.

FDA approval order statement

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested approval to remove the non-tamperproof battery door in the HiResolution Bionic Ear System external processor and replace it with a validated tamperproof door in the packaged configuration of the M Zn-Air Battery Pak (CI-5501).
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Ear, Nose, Throat
Decision date
Sep 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P960058/S177
Regulatory pathway
PMA supplement
Product code
MCM
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, cochlear.

Product code
MCM
FDA device class
3

For the original device and its historical approval scope, see PMA P960058. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P960058 · Original PMA

    CLARION MULTI-STRATEGY COCHLEAR IMPLANT

  2. P960058/S177 received

    Application receipt date recorded by FDA.

  3. P960058/S177 · FDA decision

    Special (Immediate Track)

  4. P960058/S178 · Related supplement

    CLARION MULTI-STRATEGY COCHLEAR IMPLANT

Timeline entries are records held by MedtechLedger for P960058. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960058

Product / regulatory recordCompanyPathwayDecision dateSource
Advanced BionicsPMA approvalJun 26, 1997FDA
Advanced BionicsPMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code MCM

Product / regulatory recordCompanyPathwayDecision dateSource
Med-El Corp.PMA supplementOct 9, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Med-El Corp.PMA approvalAug 20, 2001FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Advanced Bionics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
28515 Westinghouse Pl., Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records